GC Biopharma

At GC Biopharma,
our R&D efforts are centered on

advancing scientific innovation
to improve lives.

SCIENCE DRIVEN
PATIENT FOCUSED

We prioritize cutting-edge research in rare diseases, immunology, and oncology, guiding projects from early discovery to clinical trials, with a comprehensive understanding of the conditions we aim to treat.

By continuously advancing our expertise in key areas-such as plasma protein production, recombinant protein technology, vaccine development, and next-generation mRNA/LNP platforms-we are building a robust pipeline of groundbreaking treatments.

Additionally, we strive to maximize the potential of our current products while expanding our portfolio with new therapies that address unmet medical needs.

R&D Focus

Our mission is to innovate for those in need,
developing treatments that fill critical gaps in healthcare
while improving public health by preventing infectious diseases.

Therapeutic Area

Rare Diseases

We are dedicated to supporting patients and their families, no matter how rare their condition.
For diseases without existing treatments, we push boundaries to develop new options and improve access.
When treatments are available, we focus on making them more effective and easier for patients to use.

GC Biopharma has been at the forefront of developing treatments for Hunter syndrome, including ‘Hunterase’, the world’s second intravenous therapy for this disease. We also led the way in gaining approval for ‘Hunterase ICV’ in Japan, offering the first-ever intracerebroventricular injection for Hunter syndrome. Clinical trials are underway to bring this treatment to Korea.

Building on our expertise in drug development and global expansion, we are advancing research in lysosomal storage diseases (LSDs). Additionally, we are focused on next-generation mRNA/LNP therapies, aiming to enhance treatment efficacy and improve patients’ quality of life.

GC Biopharma has built a diverse portfolio of hemophilia treatments, including plasma-derived therapies like ‘GreenEight’ and ‘GreenMono’, along with the recombinant therapy ‘GreenGene F’.

‘GreenGene F’ is the third-generation recombinant hemophilia treatment developed globally, and we are currently advancing next-generation long-acting hemophilia therapies designed to extend treatment duration. In addition to hemophilia, our research continues to expand the pipeline for bleeding disorders, including von Willebrand disease.

Vaccines

The importance of vaccines in global public health has never been more evident.
At GC Biopharma, we are dedicated to preventing infectious diseases, driven by the belief that proactive healthcare and prevention are key to protecting society.

GC Biopharma’s journey in vaccine development began with Hepavax-B, Hantavax, and Varicella Vaccine, all aimed at improving public health. We have consistently demonstrated our ability to respond swiftly during pandemics, such as the swine flu, by quickly developing, producing, and distributing vaccines to protect public safety.

Recently, our flu vaccine ‘GC FLU Quadrivalent’ and the chickenpox vaccine ‘BARYCELA’ received WHO PQ approval, affirming our international standing in for both product quality and technology. To support our global expansion, we continue to invest in these areas. Additionally, we are advancing research on key vaccines, including the BCG vaccine for routine immunization and the anthrax vaccine for bioterrorism preparedness. We are also exploring the potential of mRNA platforms to tackle a range of infectious diseases and future pandemics.

Immunology

We develop therapies that modulate immune responses to provide new treatment options for various diseases,
including autoimmune conditions.

At GC Biopharma, we are advancing research into immune disorders such as Primary Immunodeficiency (PID) and Idiopathic Thrombocytopenic Purpura (ITP). Our immunoglobulin therapy, derived from purified human plasma, includes ‘IV-Globulin’ (or Alyglo) and is widely used for treating various autoimmune diseases. Our ongoing research aims to broaden its therapeutic applications, enhance patient convenience, and improve product safety.

We are expanding our research into chronic inflammatory immune disorders with high unmet needs where current treatments fall short. Our focus is on developing innovative therapies leveraging cutting-edge platforms including targeted protein degradation, mRNA, and antibody technologies.

Platform Technology

Plasma Derivative Protein

Blood is an essential, irreplaceable resource that cannot be artificially created, making it crucial for producing life-saving medicines. At GC Biopharma, we collect blood from global sources and use advanced purification processes to produce safe, high-quality therapeutics. We are continually enhancing our technology to increase the yield of medicines from each unit of blood and minimize waste during production, ensuring that every drop is fully utilized to benefit patients.

We are also focused on improving yield and developing new products to reach more patients. To ensure the highest level of safety, we are advancing purification technologies to remove impurities such as clotting factors, which are a leading cause of thromboembolism.

Plasma Derivation Protein

Improving Yield

Research aimed at increasing the volume of medicine produced per liter of plasma.

Expanding Product Range

Ongoing R&D into products such as albumin, immunoglobulins, and coagulation factors.

Virus Removal/Inactivation

Techniques like heat treatment, solvent/detergent (S/D) treatment, and nanofiltration to prevent viral contamination from blood-derived products.

Reducing Impurities

Enhancing the removal of non-target proteins to ensure safer medicines, including technologies to reduce clotting factors, a primary cause of thromboembolism¹⁾

1) Patent registered for clotting factor removal technology in 2019.

Recombinant Protein

To stay globally competitive, GC Biopharma has expanded its focus to recombinant protein therapeutics, building on our expertise in plasma-derived and vaccine products. Our successes include developing 'GreenGene F' for hemophilia and 'Hunterase' and 'Hunterase ICV' for Hunter syndrome, marking significant advancements in the treatment of rare diseases. We remain committed to high quality and productivity as we continue our research into recombinant protein therapies.

Antibody
Development

Using a bispecific antibody-based platform to develop therapeutics fo various diseases.
Cell Line
Development

Utilizing a
to rapidly identify cell lines that ensure optimal yield and target quality.
Culture
Process

Employing cutting-edge in silico modeling to enhance culture processes and reduce development time.
Purification
Process

Creating proprietary platforms tailored to research objectives and implementing
to enhance productivity and meet quality targets.

mRNA/LNP Technology

At GC Biopharma, we are actively researching mRNA/LNP platforms to strengthen our ability to develop innovative therapies. The mRNA platform provides a faster, more flexible approach compared to traditional drug development methods, with potential applications in rare diseases, immunological disorders, and cancer vaccines. Lipid Nanoparticles (LNPs) act as carriers, ensuring the safe and precise delivery of mRNA to targeted cells and tissues within the body.

Additionally, GC Biopharma is building mRNA production facilities to internalize the technology, build expertise, and engage in collaborative research to respond swiftly to future pandemics, contributing to public health improvements.

mRNA design

Designing mRNA by optimizing UTR and codon sequences using AI-based technology.
LNP design

Using AI. SAR* -based our proprietary lipid/LNP design, target cellsmRNA is delivered to organ-specific.

*SAR : Structure Activity Relationship
mRNA/LNP
manufacturing

Customizing our LNP technology to enhance the delivery of vaccines and a wide range of therapies.